Invalid science

From Wikipedia, the free encyclopedia
Jump to: navigation, search

Invalid science consists of scientific claims based on experiments that cannot be reproduced or that are contradicted by experiments that can be reproduced. Recent analyses indicate that the proportion of invalid claims in the scientific literature is steadily increasing.[1] The number of retractions has grown tenfold over the past decade. But they still make up no more than 0.2% of the 1.4m papers published annually in scholarly journals.[2]

The U.S. Office of Research Integrity (ORI), investigates scientific misconduct.[3]


Science magazine ranked first for the number of articles retracted at 70, just edging out PNAS, which retracted 69. Thirty-two of Science's retractions were due to fraud or suspected fraud, and 37 to error. A subsequent "retraction index" indicated that journals with relatively high impact factors, such as Science, Nature and Cell, had a higher rate of retractions. Under 0.1% of papers in PubMed had were retracted of more than 25 million papers going back to the 1940s.[3][4]

The fraction of retracted papers due to scientific misconduct was estimated at two-thirds, according to studies of 2047 papers published since 1977. Misconducted included fraud and plagiarism. Another one-fifth were retracted because of mistakes, and the rest were pulled for unknown or other reasons.[3]

A separate study analyzed 432 claims of genetic links for various health risks that vary between men and women. Only one of these claims proved to be consistently reproducible. Another meta review, found that of the 49 most-cited clinical research studies published between 1990 and 2003. more than 40 percent of them were later shown to be either totally wrong or significantly incorrect.[5][6]

Biological sciences[edit]

In 2012 biotech firm Amgen was able to reproduce just six of 53 important studies in cancer research. Earlier, a group at Bayer, a drug company, successfully repeated only one fourth of 67 important papers. In 2000-10 roughly 80,000 patients took part in clinical trials based on research that was later retracted because of mistakes or improprieties.[1]


Nathan Mhyrvold failed repeatedly to replicate the findings of several papers on dinosaur growth. Dinosaurs added a layer to their bones each year. Tyrannosaurus rex was thought to have increased in size by more than 700 kg a year, until Mhyrvold showed that this was a factor of 2 too large. In 4 of 12 papers he examined, the original data had been lost. In three, the statistics were correct, while three had serious errors that invalidated their conclusions. Two papers mistakenly relied on data from these three. He discovered that some of the paper's graphs did not reflect the data. In one case, he found that only four of nine points on the graph came from data cited in the paper.[7]

Major retractions[edit]

Torcetrapib was originally hyped as a drug that could block a protein that converts HDL cholesterol into LDL with the potential to “redefine cardiovascular treatment.” One clinical trial showed that the drug could increase HDL and decrease LDL. Two days after Pfizer announced its plans for the drug, it ended the Phase III clinical trial due to higher rates of chest pain and heart failure and a 60 percent increase in overall mortality. Pfizer had invested more than $1 billion in developing the drug.[5]

An in-depth review of the most highly cited biomarkers (whose presence are used to infer illness and measure treatment effects) claimed that 83 percent of supposed correlations became significantly weaker in subsequent studies.Homocysteine is an amino acid that whose levels correlated with heart disease. However, a 2010 study showed that lowering homocysteine by nearly 30 percent had no effect on heart attack or stroke.[5]


"Priming" studies claim that decisions can be influenced by apparently irrelevant events that a subject witnesses just before making a choice. Nobel Prize-winner Daniel Kahneman allege that much of it is poorly founded. Researchers have been unable to replicate some of the more widely cited examples. A paper in PLoS ONE reported that nine separate could not reproduce a study purporting to show that thinking about a professor before taking an intelligence test leads to a higher score than imagining a football hooligan.[2]

Potential causes[edit]


In the 1950s, when academic research accelerated during the cold war, the total number of scientists was a few hundred thousand. In the new century 6m-7m researchers are active. The number of research jobs has not matched this increase. Every year six new PhDs compete for every academic post. Replicating other researcher’s results is not perceived to be valuable. The struggle to compete encourages exaggeration of findings and biased data selection. A recent survey found that one in three researchers knows of a colleague who has at least somewhat distorted their results.[1]

Publication bias[edit]

Major journals reject in excess of 90% of submitted manuscripts and tend to favor the most dramatic claims. The statistical measures that researchers use to test their claims allow a fraction of false claims to appear valid. Invalid claims are more likely to be dramatic (because they are false.) Without replication, such errors are less likely to be caught.[1]

Conversely, failures to prove a hypothesis are rarely even offered for publication. “Negative results” now account for only 14% of published papers, down from 30% in 1990. Knowledge of what is not true is as important as of what is true.[1]

Peer review[edit]

Peer review is the primary validation technique employed by scientific publications. However, a prominent medical journal tested the system and found major failings. It supplied research with induced errors and found that most reviewers failed to spot the mistakes, even after being told of the tests.[1]

A pseudonymous fabricated paper on the effects of a chemical derived from lichen on cancer cells was submitted to 304 journals peer review. The paper was filled with errors study design, analysis and interpretation. 157 lower-rated journals accepted it. Another study sent an article containing eight deliberate mistakes in study design, analysis and interpretation to more than 200 of the British Medical Journal’s regular reviewers. On average, they reported fewer than two of the problems.[2]

Peer reviewers typically do not re-analyse data from scratch, checking only that the authors’ analysis is properly conceived.[2]


Type I and type II errors[edit]

Scientists divide errors into type I, incorrectly asserting the truth of a hypothesis (false positive) and type II, rejecting a correct hypothesis (false negative). Statistical checks assess the probability that data which seem to support a hypothesis come about simply by chance. If the probability is less than 5%, the evidence is rated “statistically significant”. One definitiomal consequence is a type one error rate of one in 20.[2]

Statistical power[edit]

In 2005 Stanford epidemiologist John Ioannidis showed that the idea that only one paper in 20 gives a false-positive result was incorrect. He claimed, “most published research findings are probably false.” He found three categories of problems: insufficient “statistical power” (avoiding type II errors); the unlikeliness of the hypothesis; and publication bias favoring novel claims.[2]

A statistically powerful study identifies factors with only small effects on data. In general studies with more repetitions that run the experiment more times on more subjects have greater power. A power of 0.8 means that of ten true hypotheses tested, the effects of two are missed. Ioannidis found that in neuroscience the typical statistical power is 0.21; another study found that psychology studies average 0.35.[2]

Unlikeliness is a measure of the degree of surprise in a result. Scientists prefer surprising results, leading them to test hypotheses that are unlikely to very unlikely. Ioannidis claimed that in epidemiology, some one in ten hypotheses should be true. In exploratory disciplines like genomics, which rely on examining voluminous data about genes and proteins, only one in a thousand should prove correct.[2]

In a discipline in which 100 out of 1,000 hypotheses are true, studies with a power of 0.8 will find 80 and miss 20. Of the 900 incorrect hypotheses, 5% or 45 will be accepted because of type I errors. Adding the 45 false positives to the 80 true positives gives 125 positive results, or 36% specious. Dropping statistical power to 0.4, optimistic for many fields, would still produce 45 false positives but only 40 true positives, less than half.[2]

Negative results are more reliable. Statistical power of 0.8 produces 875 negative results of which only 20 are false, giving an accuracy of over 97%. Negative results however account for a minority of published results, varying by discipline. A study of 4,600 papers found that the proportion of published negative results dropped from 30% to 14% between 1990 and 2007.[2]

Subatomic physics sets an acceptable false-positive rate of one in 3.5m (known as the five-sigma standard). However, even this does not provide perfect protection. The problem invalidates some 3/4s of machine learning studies according to one review.[2]

Statistical significance[edit]

Statistical significance is a measure for testing statistical correlation. It was invented by English mathematician Ronald Fisher in the 1920s. It defines a “significant” result as any data point that would be produced by chance less than 5 (or more stringently, 1) percent of the time. A significant result is widely seen as an important indicator that the correlation is not random.[5]

While correlations track the relationship between truly independent measurements, such as smoking and cancer, they are much less effective when variables cannot be isolated, a common circumstance in biological systems. For example, statistics found a high correlation between lower back pain and abnormalities in spinal discs, although it was later discovered that serious abnormalities were present in two-thirds of pain-free patients.[5]

Minimum threshold publishers[edit]

Journals such as PLoS One use a “minimal-threshold” standard, seeking to publish as much science as possible, rather than to pick out the best work. Their peer reviewers assess only whether a paper is methodologically sound. Almost half of their submissions are still rejected on that basis.[2]

Unpublished research[edit]

Only 22% of the clinical trials financed by the National Institutes of Health (NIH) released summary results within one year of completion, even though the NIH requires it. Fewer than half published within 30 months; a third remained unpublished after 51 months.[2] When other scientists rely on invalid research, they may waste time on lines of research that are themselves invalid. The failure to report failures means that researchers waste money and effort exploring blind alleys already investigated by other scientists.[1]


In 21 surveys of academics (mostly in the biomedical sciences but also in civil engineering, chemistry and economics) carried out between 1987 and 2008, 2% admitted fabricating data, but 28% claimed to know of colleagues who engaged in questionable research practices.[2]

Lack of access to data and software[edit]

Clinical trials are generally too costly to rerun. Access to trial data is the only practical approach to reassessment. A campaign to persuade pharmaceutical firms to make all trial data available won its first convert in February 2013 whenGlaxoSmithKline became the first to agree.[2]

Software used in a trial is generally considered to be proprietary intellectual property and is not available to replicators, further complicating matters. Journals that insist on data-sharing tend not to do the same for software.[2]

Even well-written papers may not include sufficient detail and/or tacit knowledge (subtle skills and extemporisations not considered notable) for the replication to succeed. One cause of replication failure is insufficient control of the protocol, which can cause disputes between the original and replicating researchers.[2]


Statistics training[edit]

Geneticists have begun more careful reviews, particularly of the use of statistical techniques. The effect was to stop a flood of specious results from genome sequencing.[1]

Protocol registration[edit]

Registering research protocols in advance and monitoring them over the course of a study can prevent researchers from modifying the protocol midstream to highlight preferred results. Providing raw data for other researchers to inspect and test can also better hold researchers to account.[1]

Post-publication review[edit]

Replacing peer review with post-publication evaluations can encourage researchers to think more about the long-term consequences of excessive or unsubstantiated claims. That system was adopted in physics and mathematics with good results.[1]


Few researchers, especially junior workers, seek opportunities to replicate others' work, partly to protect relationships with senior researchers.[2]

Reproduction benefits from access to the original study's methods and data. More than half of 238 biomedical papers published in 84 journals failed to identify all the resources (such as chemical reagents) necessary to reproduce the results. In 2008 some 60% of researchers said they would share raw data; in 2013 just 45% do. Journals have begun to demand that at least some raw data be made available, although only 143 of 351 randomly selected papers covered by some data-sharing policy actually complied.[2]

The Reproducibility Initiative is a service allowing life scientists to pay to have their work validated by an independent lab. In October 2013 the initiative received funding to review 50 of the highest-impact cancer findings published between 2010 and 2012. Blog Syn is a website run by graduate students that is dedicated to reproducing chemical reactions reported in papers.[2]

In 2013 replication efforts received greater attention. Nature and related publications introduced an 18-point checklist for life science authors in May.[8] in its effort to ensure that its published research can be reproduced. Expanded "methods" sections and all data were to be available online. The Centre for Open Science opened as an independent laboratory focused on replication. The journal Perspectives on Psychological Science announced a section devoted to replications. Another project announced plans to replicate 100 studies published in the first three months of 2008 in three leading psychology journals.[2]

Major funders, including the European Research Council, the US National Science Foundation and Research Councils UK have not changed their preference for new work over replications.[2]

See also[edit]


  1. ^ a b c d e f g h i j "Problems with scientific research: How science goes wrong". The Economist. 2013-10-19. Retrieved 2013-10-19. 
  2. ^ a b c d e f g h i j k l m n o p q r s t u v "Unreliable research: Trouble at the lab". The Economist. 2013-10-19. Retrieved 2013-10-22. 
  3. ^ a b c "Misconduct, Not Mistakes, Causes Most Retractions of Scientific Papers | Science/AAAS | News". 2012-10-01. Retrieved 2013-10-19. 
  4. ^ Fang, F. C.; Steen, R. G.; Casadevall, A. (2012). "Misconduct accounts for the majority of retracted scientific publications". Proceedings of the National Academy of Sciences. 109 (42): 17028. PMC 3479492Freely accessible. PMID 23027971. doi:10.1073/pnas.1212247109. 
  5. ^ a b c d e Lehrer, Jonah (December 16, 2011). "Trials and Errors: Why Science Is Failing Us". Wired. Retrieved October 2013.  Check date values in: |access-date= (help)
  6. ^ "Highly cited studies often refuted". Retrieved 2013-10-22. 
  7. ^ Anonymous (2013-12-21). "Palaeontology: A bone to pick". The Economist. Retrieved 2014-04-17. 
  8. ^ Reporting Checklist For Life Sciences Articles

External links[edit]